Kymera Therapeutics Inc (NAS:KYMR)
$ 35.94 0.85 (2.42%) Market Cap: 2.21 Bil Enterprise Value: 1.72 Bil PE Ratio: 0 PB Ratio: 3.03 GF Score: 60/100

Kymera Therapeutics Inc at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 05:50PM GMT
Release Date Price: $27.83 (-8.24%)
Jin Law;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

Okay. We're going to get started. My name is Rich Law. I'm a senior biotech analyst at CS. I'd like to welcome our -- Kymera for next fireside chat. We're joined by Nello Mainolfi, CEO. Nello, welcome.

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks, Richard. Thanks for the invite.

Jin Law;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

So before we jump into Q&A, any opening remarks from you?

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Yes. So first, thanks for the invitation. Beautiful location. Luckily, today is a good day.

I just want to remind everybody, Kymera is a company focused on taking targeted protein degradation and building a fully integrated commercial-stage biotech in a disease-agnostic and technology-agnostic manner. Obviously, we've

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot